Atelerix, a UK-based biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, has signed an exclusive distribution agreement with MineBio, a leading Chinese supply chain and logistics organisation.
Under the terms of the agreement, MineBio will act as the sole distribution partner for Atelerix’s products in China, providing solutions to traditional cryopreservation challenges by enabling the storage and transport of temperature-sensitive biomaterials without freezing.
Atelerix’s patented hydrogels directly address cryologistic bottlenecks by physically encapsulating cells, stabilising membrane integrity, and preserving biological function during transport. Samples can remain in a ready-to-use state at ambient temperatures for up to two weeks, eliminating the built-in costs and inefficiencies of the ultra-cold chain. By simplifying logistics, the technology reduces waste and energy consumption, de-escalates shipping and handling protocols, and minimises loss in cell viability that is often seen during cryopreservation and recovery.
China accounted for 37% of global clinical trials in 2024, with its biotechnology industry demonstrating a CAGR of 19.8% 2024 - 2030. Recognising the significant market potential, including rapid growing demand for advanced in vitro models and biomaterials, the distribution agreement with MineBio strategically positions Atelerix to support and scale within the region.
